Alpha Compute Corp

ALP · Nasdaq

Share price · ALP

$2.31-5.82 (-71.65%) 3M

close as of 2026-11-18 · 24h delayed · vol 17K (0.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ALP's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 24 Sep 2026+23.6%
  2. 10 Sep 2026-31.5%
  3. 3 Sep 2026-35.8%
  4. 16 Jul 2026-36.1%

    Nothing announced by ALP that day or the session before.

  5. 13 Jul 2026+22.0%
  6. 26 May 2026+24.1%
  7. 14 May 2026+23.2%
  8. 12 May 2026+15.5%
  9. 24 Apr 2026+18.5%
  10. 23 Apr 2026-20.4%

Share of unusual movement by asset

For each asset, the share of ALP's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—2%
Sessions with no dated event—98%

No dated announcements about its assets since 2 Jul 2024.

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 1/2
adenosine A2ASmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
Adenosine A2b receptorSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (2)
2026-12-31 Financial ReportEarnings report
Expected report date 2027-01-11 · Fiscal period ending 2026-12-31
What to watch
2026-09-30 Financial ReportEarnings report
Expected report date 2027-01-11 · Fiscal period ending 2026-09-30
What to watch
2028 (1)
December 2028 (1)
TT-10 + TT-4Phase 1/2Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
Est. primary completion 2028-12-01 · NCT04969315 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (11)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3—$0.6M$0.2M$10Mreport ↗
View 10 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q3—$0.7M$1.8M$1.4M-$1.6M operating cash flowreport ↗
2024-Q2—$1.3M$3.3M$1.7M-$1.7M operating cash flowreport ↗
2023-Q4—$2.8M$5.3M$39M-$3.4M operating cash flowreport ↗
2023-Q3—$4.2M$3.5M$5.2M-$4.3M operating cash flowreport ↗
2023-Q2—$3.6M$7.7M$5.9M-$3.5M operating cash flowreport ↗
2022-Q4—$2.5M$13M$7.5M-$2.7M operating cash flowreport ↗
2022-Q3—$1.6M$15M$1.1M-$2.5M operating cash flowreport ↗
2022-Q2—$1.9M$21M$1.6M-$2.2M operating cash flowreport ↗
2021-Q4—$1.9M$26M$4.2M-$1.7M operating cash flowreport ↗
2021-Q3—$1.3M$27M$2.9Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$3.1M$1.7M$1.7M-$5.5M operating cash flowreport ↗

Portage Biotech reported R&D spend of $3.13M, down 75.0% YoY, cash and equivalents of $1.67M, and a net loss of $6.78M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$13M$5.0M$19M-$14M operating cash flowreport ↗
2023-FY—$8.2M$11M$26M-$12M operating cash flowreport ↗
2022-FY—$6.8M$23M$4.8M-$6.8M operating cash flowreport ↗
2021-FY—$7.3M$2.8M$4.3M-$4.3M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 12 purchases ($315K), 1 sale ($2K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-07Villani Fiorenzo · director, See RemarksOpen-market purchase5,150$3.80$20KForm 4
2026-09-22Villani Fiorenzo · director, See RemarksOpen-market purchase10,000$4.40$44KForm 4
2026-09-16Villani Fiorenzo · director, See RemarksOpen-market purchase4,265$4.05$17KForm 4
2026-09-15Villani Fiorenzo · director, See RemarksOpen-market purchase10,382$4.07$42KForm 4
2026-09-15Villani Fiorenzo · director, See RemarksOpen-market purchase7,900$4.15$33KForm 4
2026-09-14Mitin Yury · See RemarksOpen-market purchase9,000$4.29$39KForm 4
2026-09-14Mitin Yury · See RemarksOpen-market sale393$4.15$2KForm 4
2026-09-14Villani Fiorenzo · director, See RemarksOpen-market purchase2,000$4.16$8KForm 4